{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T14:10:35Z","timestamp":1793801435485,"version":"4.6.1"},"reference-count":211,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Although current treatments for autoimmune diseases can effectively control symptoms, they rarely lead to cures and often require lifelong use, accompanied by considerable adverse effects. This emphasizes the urgent need for more targeted therapies that offer long-term efficacy and curative potential. Chimeric antigen receptor (CAR) T-cell therapy presents a promising option by specifically targeting and eliminating autoreactive B cells, with the potential to reset the patient\u2019s immune system and promote long-term immune balance. Originally developed for treating hematologic malignancies, where it has achieved remarkable success, recent studies have demonstrated substantial promise of CAR T-cell therapy, such as systemic lupus erythematosus (SLE) and myasthenia gravis. This article provides an overview of the current progress in CAR T-cell therapy for autoimmune diseases, focusing on five key approaches: CD19-targeted CAR T cells, CAR T cells targeting long-lived plasma cells, CAR T cells targeting specific autoantibodies, organ-specific CAR regulatory T cells (Treg cells), and mRNA-engineered CAR T cells. Additionally, this article discusses strategies for optimizing CAR T-cell therapy, including \u201coff-the-shelf\u201d allogeneic CAR T-cell therapy, combined CAR T-cell therapy, establishing timely consensus guidelines for their application in autoimmune diseases, and risk stratification strategies aimed at enhancing the personalization of treatments and minimizing adverse effects. While current research results are promising, further large-scale clinical trials and long-term follow-up are essential to thoroughly evaluate the safety and efficacy of CAR T-cell therapy in autoimmune diseases.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1613878","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T04:10:49Z","timestamp":1754971849000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":32,"title":["CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon"],"prefix":"10.3389","volume":"16","author":[{"given":"Dehong","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijun Y.","family":"Xu-Monette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kepeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinchang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsheng","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken H.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.01.017","article-title":"Autoantibodies 2015: From diagnostic biomarkers toward prediction, prognosis and prevention","volume":"14","author":"Damoiseaux","year":"2015","journal-title":"Autoimmun Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12395","article-title":"Human autoimmune diseases: a comprehensive update","volume":"278","author":"Wang","year":"2015","journal-title":"J Internal Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.cell.2020.03.007","article-title":"Challenges, progress, and prospects of developing therapies to treat autoimmune diseases","volume":"181","author":"Fugger","year":"2020","journal-title":"Cell"},{"key":"B4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jaut.2014.02.008","article-title":"Infection and autoimmunity in Sjogren\u2019s syndrome: a clinical study and comprehensive review","volume":"51","author":"Kivity","year":"2014","journal-title":"J Autoimm"},{"key":"B5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jaut.2014.03.005","article-title":"Long term effect of gut microbiota transfer on diabetes development","volume":"53","author":"Peng","year":"2014","journal-title":"J Autoimm"},{"key":"B6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.coi.2014.08.005","article-title":"Molecular mechanisms for contribution of MHC molecules to autoimmune diseases","volume":"31","author":"Sollid","year":"2014","journal-title":"Curr Opin Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2174\/138955708785132756","article-title":"Azathioprine in multiple sclerosis","volume":"8","author":"Invernizzi","year":"2008","journal-title":"Mini Reviews Medicinal Chem"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1210\/me.2011-0068","article-title":"Minireview: Glucocorticoids in autoimmunity: unexpected targets and mechanisms","volume":"25","author":"Flammer","year":"2011","journal-title":"Mol Endocrinol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2013.10.029","article-title":"Methotrexate: new uses for an old drug","volume":"164","author":"Hashkes","year":"2014","journal-title":"J Pediatr"},{"key":"B10","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"New Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1913146","article-title":"CAR-T cell persistence in the treatment of leukemia and lymphoma","volume":"62","author":"Gupta","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"B12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.blre.2022.100929","article-title":"Current state and next-generation CAR-T cells in multiple myeloma","volume":"54","author":"Manier","year":"2022","journal-title":"Blood Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-1683","article-title":"Next-generation CAR T-cell therapies","volume":"12","author":"Young","year":"2022","journal-title":"Cancer Discov"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-022-00537-5","article-title":"CAR-based therapies: opportunities for immuno-medicine beyond cancer","volume":"4","author":"Aghajanian","year":"2022","journal-title":"Nat Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.10.026","article-title":"CAR T therapy extends its reach to autoimmune diseases","volume":"185","author":"Baker","year":"2022","journal-title":"Cell"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2024.07.005","article-title":"Frontiers in CAR-T cell therapy for autoimmune diseases","volume":"45","author":"Li","year":"2024","journal-title":"Trends Pharmacol Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-024-01139-z","article-title":"Advancements and challenges in CAR T cell therapy in autoimmune diseases","volume":"20","author":"Schett","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06243-w","article-title":"CAR T therapy beyond cancer: the evolution of a living drug","volume":"619","author":"Baker","year":"2023","journal-title":"Nature"},{"key":"B20","doi-asserted-by":"publisher","first-page":"024","DOI":"10.1038\/s41584-024-01139-z","article-title":"Advancements and challenges in CAR T cell therapy in autoimmune diseases","volume":"6","author":"Schett","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1126\/science.1071059","article-title":"The danger model: a renewed sense of self","volume":"296","author":"Matzinger","year":"2002","journal-title":"Science"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1100359","article-title":"Systemic lupus erythematosus","volume":"365","author":"Tsokos","year":"2011","journal-title":"New Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0092-8674(00)81107-1","article-title":"Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system","volume":"85","author":"Steinman","year":"1996","journal-title":"Cell"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.25.022106.141557","article-title":"IL-17 family cytokines and the expanding diversity of effector T cell lineages","volume":"25","author":"Weaver","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.autrev.2020.102743","article-title":"An updated advance of autoantibodies in autoimmune diseases","volume":"20","author":"Xiao","year":"2021","journal-title":"Autoimmun Rev"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/ncprheum0895","article-title":"Nature and functions of autoantibodies","volume":"4","author":"Elkon","year":"2008","journal-title":"Nat Clin Pract Rheumatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"New Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1172\/JCI78088","article-title":"Mechanisms of human autoimmunity","volume":"125","author":"Rosenblum","year":"2015","journal-title":"J Clin Invest"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05415-0","article-title":"Type 1 diabetes: new perspectives on disease pathogenesis and treatment","volume":"358","author":"Atkinson","year":"2001","journal-title":"Lancet"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200108023450506","article-title":"Autoimmune diseases","volume":"345","author":"Davidson","year":"2001","journal-title":"New Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0905750","article-title":"Graves\u2019 ophthalmopathy","volume":"362","author":"Bahn","year":"2010","journal-title":"New Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/nature08933","article-title":"Genetics, pathogenesis and clinical interventions in type 1 diabetes","volume":"464","author":"Bluestone","year":"2010","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/nature03724","article-title":"Cellular and genetic mechanisms of self tolerance and autoimmunity","volume":"435","author":"Goodnow","year":"2005","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-1-6","article-title":"Systemic lupus erythematosus","volume":"1","author":"Manson","year":"2006","journal-title":"Orphanet J Rare Dis"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2017.02.006","article-title":"Immunopathogenesis of rheumatoid arthritis","volume":"46","author":"Firestein","year":"2017","journal-title":"Immunity"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S0733-8635(05)70010-3","article-title":"The risks of systemic corticosteroid use","volume":"16","author":"Lester","year":"1998","journal-title":"Dermatol Clin"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-200110000-00006","article-title":"Side effects of corticosteroid therapy","volume":"33","author":"Buchman","year":"2001","journal-title":"J Clin Gastroenterol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)60159-7","article-title":"The effects of corticosteroids on bone: osteonecrosis (avascular necrosis of the bone)","volume":"103","author":"Weldon","year":"2009","journal-title":"\u201cAnnals Allergy Asthma Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/15360288.2017.1298689","article-title":"The risks of chronic corticosteroid exposure","volume":"31","author":"Money","year":"2017","journal-title":"J Pain Palliative Care Pharmacother"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1191\/0961203303lu1028oa","article-title":"Cyclophosphamide: new approaches for systemic lupus erythematosus","volume":"13","author":"Petri","year":"2004","journal-title":"Lupus"},{"key":"B41","first-page":"24","article-title":"Treatment with tacrolimus in autoimmune diseases","volume":"48","author":"S\u00e1daba","year":"2004","journal-title":"Rev Med Univ Navarra"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2014.962996","article-title":"Methotrexate: an old new drug in autoimmune disease","volume":"10","author":"Cipriani","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1586\/17512433.2015.1019343","article-title":"Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases","volume":"8","author":"Fragoso","year":"2015","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.4067\/S0034-98872016000200012","article-title":"Hydroxychloroquine for autoimmune diseases","volume":"144","author":"Danza","year":"2016","journal-title":"Rev Med Chile"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.02.022","article-title":"Autoimmune hepatitis: Mycophenolate mofetil vs. azathioprine as first-line therapy","volume":"81","author":"\u015eim\u015fek","year":"2024","journal-title":"J Hepatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2013.08.003","article-title":"Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs","volume":"43","author":"Solomon","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/S0958-1669(02)00355-5","article-title":"Monoclonal antibodies in immune and inflammatory diseases","volume":"13","author":"Andreakos","year":"2002","journal-title":"Curr Opin Biotechnol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/rheumatology\/kead448","article-title":"Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases","volume":"63","author":"Taylor","year":"2024","journal-title":"Rheumatology"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2019.07.023","article-title":"Rituximab in autoimmune pemphigoid diseases: Indications, optimized regimens, and practice gaps","volume":"38","author":"Thomas","year":"2020","journal-title":"Clinics In Dermatol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1177\/1759720X17690474","article-title":"Belimumab in systemic lupus erythematosus (SLE): evidence-to-date and clinical usefulness","volume":"9","author":"Guerreiro Castro","year":"2017","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"B51","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/cts.13688","article-title":"Upadacitinib: Mechanism of action, clinical, and translational science","volume":"17","author":"Mohamed","year":"2024","journal-title":"Clin Trans Sci"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.080960","article-title":"Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response","volume":"67","author":"Thurlings","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/art.27541","article-title":"Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry","volume":"62","author":"Terrier","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12220","article-title":"A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function","volume":"13","author":"Kamburova","year":"2013","journal-title":"Am J Transpl"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e000384","DOI":"10.1136\/rmdopen-2016-000384","article-title":"Rituximab in early systemic sclerosis","volume":"3","author":"Boonstra","year":"2017","journal-title":"RMD Open"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1177\/096120339300200304","article-title":"Immune ablation with stem-cell rescue: a possible cure for systemic lupus erythematosus","volume":"2","author":"Marmont","year":"1993","journal-title":"Lupus"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703868","article-title":"The promise of hematopoietic stem cell transplantation for autoimmune diseases","volume":"31","author":"Burt","year":"2003","journal-title":"Bone Marrow Transpl"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2249.2005.02806.x","article-title":"Haematopoietic stem cell transplantation in the treatment of severe autoimmune disease: results from phase I\/II studies, prospective randomized trials and future directions","volume":"141","author":"Tyndall","year":"2005","journal-title":"Clin And Exp Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.03.008","article-title":"Autologous hematopoietic stem cell transplantation in Systemic Lupus Erythematosus and antiphospholipid syndrome: A systematic review","volume":"16","author":"Leone","year":"2017","journal-title":"Autoimmun Rev"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017010041","article-title":"Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases","volume":"1","author":"Snowden","year":"2017","journal-title":"Blood Adv"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-070119-115617","article-title":"Hematopoietic stem cell transplantation for autoimmune disease","volume":"72","author":"Alexander","year":"2021","journal-title":"Annu Rev Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-035766","article-title":"Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used","volume":"109","author":"Loh","year":"2007","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-336156","article-title":"Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party","volume":"118","author":"Daikeler","year":"2011","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2005.03.003","article-title":"Hemopoietic stem cell transplantation in rheumatic diseases\u2013an update","volume":"4","author":"de Buys","year":"2005","journal-title":"Autoimmun Rev"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"New Engl J Med"},{"key":"B67","doi-asserted-by":"publisher","first-page":"44","DOI":"10.4110\/in.2016.16.1.44","article-title":"Dendritic cell-based immunotherapy for rheumatoid arthritis: from bench to bedside","volume":"16","author":"Ahmed","year":"2016","journal-title":"Immune Netw"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/nri2132","article-title":"Tolerogenic dendritic cells and the quest for transplant tolerance","volume":"7","author":"Morelli","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"290ra287","DOI":"10.1126\/scitranslmed.aaa9301","article-title":"Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients","volume":"7","author":"Benham","year":"2015","journal-title":"Sci Trans Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-0472","article-title":"Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients","volume":"34","author":"Giannoukakis","year":"2011","journal-title":"Diabetes Care"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201141835","article-title":"Stable antigen-specific T-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients","volume":"42","author":"Ra\u03cach-Regu\u00e9","year":"2012","journal-title":"Eur J Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00235","article-title":"Natural regulators\u201d: NK cells as modulators of T cell immunity","volume":"7","author":"Schuster","year":"2016","journal-title":"Front Immunol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/biom12010004","article-title":"Role of IL-10-producing natural killer cells in the regulatory mechanisms of inflammation during systemic infection","volume":"12","author":"Martinez-Espinosa","year":"2021","journal-title":"Biomolecules"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2005.09.008","article-title":"Early liaisons between cells of the innate immune system in inflamed peripheral tissues","volume":"26","author":"Moretta","year":"2005","journal-title":"Trends In Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22339","article-title":"Interleukin-2\/interleukin-2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation","volume":"69","author":"Hao","year":"2011","journal-title":"Ann Neurol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1230735","article-title":"Ozanimod-mediated remission in experimental autoimmune encephalomyelitis is associated with enhanced activity of CNS CD27(low\/-) NK cell subset","volume":"15","author":"Kamyan","year":"2024","journal-title":"Front Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1002\/iub.2296","article-title":"CRISPR\/Cas9 gene editing: A new therapeutic approach in the treatment of infection and autoimmunity","volume":"72","author":"Mohammadzadeh","year":"2020","journal-title":"IUBMB Life"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/bs.pmbts.2024.07.011","article-title":"Current progress in CRISPR-Cas systems for autoimmune diseases","volume":"208","author":"Israr","year":"2024","journal-title":"Prog Mol Biol Trans Sci"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1711886","article-title":"Tragedy, perseverance, and chance - the story of CAR-T therapy","volume":"377","author":"Rosenbaum","year":"2017","journal-title":"New Engl J Med"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"New Engl J Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/s44321-024-00043-z","article-title":"B cell lineage reconstitution underlies CAR-T cell therapeutic efficacy in patients with refractory myasthenia gravis","volume":"16","author":"Tian","year":"2024","journal-title":"EMBO Mol Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02321-0","article-title":"CAR-Ts sweep into autoimmunity","volume":"42","author":"Harrison","year":"2024","journal-title":"Nat Biotechnol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00530-z","article-title":"A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains","volume":"18","author":"Cappell","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.3390\/ijms19113455","article-title":"Development of inducible CD19-CAR T cells with a tet-on system for controlled activity and enhanced clinical safety","volume":"19","author":"Gu","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225785","article-title":"BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Wang","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B88","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1073\/pnas.1524155113","article-title":"Switch-mediated activation and retargeting of CAR-T cells for B-cell Malignancies","volume":"113","author":"Rodgers","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2030164","article-title":"Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy","volume":"384","author":"Chong","year":"2021","journal-title":"New Engl J Med"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018893","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2024.03.006","article-title":"Therapeutic intersections: Expanding benefits of CD19 CAR T cells from cancer to autoimmunity","volume":"31","author":"Sosnoski","year":"2024","journal-title":"Cell Stem Cell"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-555169","article-title":"A unique population of IgG-expressing plasma cells lacking CD19 is enriched in human bone marrow","volume":"125","author":"Mei","year":"2015","journal-title":"Blood"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy","volume":"128","author":"Bhoj","year":"2016","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.06.016","article-title":"Long-lived plasma cells are contained within the CD19(-)CD38(hi)CD138(+) subset in human bone marrow","volume":"43","author":"Halliley","year":"2015","journal-title":"Immunity"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000717","article-title":"Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy","volume":"3","author":"Hill","year":"2019","journal-title":"Blood Adv"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00375-7","article-title":"Anti-CD19 CAR T cells for refractory myasthenia gravis","volume":"22","author":"Haghikia","year":"2023","journal-title":"Lancet Neurol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of Malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J Clin Oncol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"eaav1648","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci Trans Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0472-1","article-title":"Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus","volume":"18","author":"Jin","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-223952","article-title":"Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells","volume":"82","author":"Bergmann","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225174","article-title":"Third-generation CD19.CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis","volume":"83","author":"Merkt","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome","volume":"401","author":"M\u00fcller","year":"2023","journal-title":"Lancet"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"Jama"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1172\/JCI18025","article-title":"BAFF selectively enhances the survival of plasmablasts generated from human memory B cells","volume":"112","author":"Avery","year":"2003","journal-title":"J Clin Invest"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1126\/science.1241146","article-title":"Diversity among memory B cells: origin, consequences, and utility","volume":"341","author":"Tarlinton","year":"2013","journal-title":"Science"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/nri3795","article-title":"The generation of antibody-secreting plasma cells","volume":"15","author":"Nutt","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(200109)31:9<2726::AID-IMMU2726>3.0.CO;2-H","article-title":"Inflamed kidneys of NZB\/W mice are a major site for the homeostasis of plasma cells","volume":"31","author":"Cassese","year":"2001","journal-title":"Eur J Immunol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1313.014","article-title":"Long-lived plasma cells and their contribution to autoimmunity","volume":"1050","author":"Hoyer","year":"2005","journal-title":"Ann New York Acad Sci"},{"key":"B113","doi-asserted-by":"publisher","first-page":"6236","DOI":"10.1038\/s41598-020-63390-0","article-title":"Analysis of the receptor BCMA as a biomarker in systemic lupus erythematosus patients","volume":"10","author":"Salazar-Camarena","year":"2020","journal-title":"Sci Rep"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-0414","article-title":"A five-year follow-up clinical study of the B cell maturation antigen chimeric antigen receptor-T cell therapy HDS269B in patients with relapsed or refractory multiple myeloma","volume":"30","author":"Chen","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B115","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41392-022-01278-3","article-title":"Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results","volume":"8","author":"Qin","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B116","doi-asserted-by":"publisher","first-page":"eadj9730","DOI":"10.1126\/sciimmunol.adj9730","article-title":"Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system autoimmunity","volume":"9","author":"Qin","year":"2024","journal-title":"Sci Immunol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.597959","article-title":"CD38: an immunomodulatory molecule in inflammation and autoimmunity","volume":"11","author":"Piedra-Quintero","year":"2020","journal-title":"Front Immunol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(200104)31:4<1261::AID-IMMU1261>3.0.CO;2-H","article-title":"Ontogeny, distribution and function of CD38-expressing B lymphocytes in mice","volume":"31","author":"Don\u00eds-Hern\u00e1ndez","year":"2001","journal-title":"Eur J Immunol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12370","article-title":"CD38 expression in early B-cell precursors contributes to extracellular signal-regulated kinase-mediated apoptosis","volume":"144","author":"Romero-Ram\u00edrez","year":"2015","journal-title":"Immunology"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.30760","article-title":"Effect of CD38 on B-cell function and its role in the diagnosis and treatment of B-cell-related diseases","volume":"237","author":"Zeng","year":"2022","journal-title":"J Cell Physiol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3390\/cells9010077","article-title":"Is there a future for anti-CD38 antibody therapy in systemic autoimmune diseases","volume":"9","author":"Benfaremo","year":"2019","journal-title":"Cells"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2023325","article-title":"Targeting CD38 with daratumumab in refractory systemic lupus erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"New Engl J Med"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"New Engl J Med"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"B125","doi-asserted-by":"publisher","first-page":"5727516","DOI":"10.1155\/2019\/5727516","article-title":"Immunotherapy deriving from CAR-T cell treatment in autoimmune diseases","volume":"2019","author":"Chen","year":"2019","journal-title":"J Immunol Res"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18482","article-title":"Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect","volume":"182","author":"Chen","year":"2020","journal-title":"Br J Dermatol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028564","article-title":"Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris","volume":"384","author":"Werth","year":"2021","journal-title":"New Engl J Med"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1172\/JCI138416","article-title":"Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris","volume":"130","author":"Lee","year":"2020","journal-title":"J Clin Invest"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25973","article-title":"B cells in the pathophysiology of myasthenia gravis","volume":"57","author":"Yi","year":"2018","journal-title":"Muscle Nerve"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00707","article-title":"Muscle-specific kinase myasthenia gravis","volume":"11","author":"Borges","year":"2020","journal-title":"Front Immunol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"556","DOI":"10.3390\/cells13060556","article-title":"MuSK myasthenia gravis-potential pathomechanisms and treatment directed against specific targets","volume":"13","author":"Dziadkowiak","year":"2024","journal-title":"Cells"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-022-01637-z","article-title":"Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells","volume":"41","author":"Oh","year":"2023","journal-title":"Nat Biotechnol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.10.001","article-title":"Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells","volume":"186","author":"Reincke","year":"2023","journal-title":"Cell"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283874","article-title":"GPIb\u03b1 CAAR T cells function like a Trojan horse to eliminate autoreactive B cells to treat immune thrombocytopenia","volume":"109","author":"Zhou","year":"2024","journal-title":"Haematologica"},{"key":"B136","doi-asserted-by":"publisher","first-page":"102376","DOI":"10.1016\/j.jaut.2019.102376","article-title":"Treg cells in health and autoimmune diseases: New insights from single cell analysis","volume":"110","author":"Scheinecker","year":"2020","journal-title":"J Autoimm"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0038","article-title":"Administration of CD4+CD25highCD127- regulatory T cells preserves \u03b2-cell function in type 1 diabetes in children","volume":"35","author":"Marek-Trzonkowska","year":"2012","journal-title":"Diabetes Care"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1002\/art.40737","article-title":"Adoptive treg cell therapy in a patient with systemic lupus erythematosus","volume":"71","author":"Dall\u2019Era","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B139","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.1038\/d41586-021-01840-z","article-title":"Creating T cells to guard against autoimmune disease","volume":"595","author":"Bender","year":"2021","journal-title":"Nature"},{"key":"B140","doi-asserted-by":"publisher","first-page":"108409","DOI":"10.1016\/j.intimp.2021.108409","article-title":"CAR Treg: A new approach in the treatment of autoimmune diseases","volume":"102","author":"Beheshti","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"B141","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3390\/biomedicines10020287","article-title":"CAR-T regulatory (CAR-treg) cells: engineering and applications","volume":"10","author":"Arjomandnejad","year":"2022","journal-title":"Biomedicines"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-022-07511-0","article-title":"Harnessing the inherent power of chimeric antigen receptor (CAR)-expressing regulatory T cells (CAR-Tregs) to treat autoimmune-related disorders","volume":"49","author":"Kahmini","year":"2022","journal-title":"Mol Biol Rep"},{"key":"B143","doi-asserted-by":"publisher","first-page":"7015","DOI":"10.3390\/ijms21197015","article-title":"Treg enhancing therapies to treat autoimmune diseases","volume":"21","author":"Eggenhuizen","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B144","doi-asserted-by":"publisher","first-page":"8415","DOI":"10.3390\/ijms22168415","article-title":"Tolerogenic dendritic cell-based approaches in autoimmunity","volume":"22","author":"Passeri","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.05.009","article-title":"Regulatory T cells and immune tolerance","volume":"133","author":"Sakaguchi","year":"2008","journal-title":"Cell"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0232-6","article-title":"T(reg) cell-based therapies: challenges and perspectives","volume":"20","author":"Raffin","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.41","article-title":"Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells","volume":"22","author":"Blat","year":"2014","journal-title":"Mol Ther"},{"key":"B148","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1186\/1742-2094-9-112","article-title":"CAR\/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery","volume":"9","author":"Fransson","year":"2012","journal-title":"J Neuroinflamm"},{"key":"B149","doi-asserted-by":"publisher","first-page":"102289","DOI":"10.1016\/j.jaut.2019.05.017","article-title":"Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes","volume":"103","author":"Tenspolde","year":"2019","journal-title":"J Autoimm"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000411","article-title":"Human CD8+ Tregs expressing a MHC-specific CAR display enhanced suppression of human skin rejection and GVHD in NSG mice","volume":"3","author":"B\u00e9zie","year":"2019","journal-title":"Blood Adv"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-022-00358-x","article-title":"Preclinical assessment of antigen-specific chimeric antigen receptor regulatory T cells for use in solid organ transplantation","volume":"30","author":"Proics","year":"2023","journal-title":"Gene Ther"},{"key":"B152","doi-asserted-by":"publisher","first-page":"102961","DOI":"10.1016\/j.jaut.2022.102961","article-title":"Flagellin-specific human CAR Tregs for immune regulation in IBD","volume":"134","author":"Boardman","year":"2023","journal-title":"J Autoimm"},{"key":"B153","doi-asserted-by":"publisher","first-page":"otaa085","DOI":"10.1093\/crocol\/otaa085","article-title":"Patients\u2019 Willingness and perspectives toward chimeric antigen receptor T-regulatory cell therapy for inflammatory bowel diseases","volume":"2","author":"Vent-Schmidt","year":"2020","journal-title":"Crohns Colitis"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1235222","article-title":"CAR-T cells and CAR-Tregs targeting conventional type-1 dendritic cell suppress experimental autoimmune encephalomyelitis","volume":"14","author":"Moorman","year":"2023","journal-title":"Front Immunol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1172\/JCI82771","article-title":"Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor","volume":"126","author":"MacDonald","year":"2016","journal-title":"J Clin Invest"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14185","article-title":"Expression of a chimeric antigen receptor specific for donor HLA class I enhances the potency of human regulatory T cells in preventing human skin transplant rejection","volume":"17","author":"Boardman","year":"2017","journal-title":"Am J Transpl"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14175","article-title":"Prevention of allograft rejection by use of regulatory T cells with an MHC-specific chimeric antigen receptor","volume":"17","author":"Noyan","year":"2017","journal-title":"Am J Transpl"},{"key":"B158","doi-asserted-by":"publisher","first-page":"e123672","DOI":"10.1172\/jci.insight.123672","article-title":"Systematic testing and specificity mapping of alloantigen-specific chimeric antigen receptors in regulatory T cells","volume":"4","author":"Dawson","year":"2019","journal-title":"JCI Insight"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2010.10.009","article-title":"Regulation of immunity and autoimmunity by B cells","volume":"22","author":"Mauri","year":"2010","journal-title":"Curr Opin Immunol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01466-0","article-title":"Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell Malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group","volume":"35","author":"Spanjaart","year":"2021","journal-title":"Leukemia"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1038\/nature15818","article-title":"Gene therapy returns to centre stage","volume":"526","author":"Naldini","year":"2015","journal-title":"Nature"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.9b04246","article-title":"Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR T cell engineering","volume":"20","author":"Billingsley","year":"2020","journal-title":"Nano Lett"},{"key":"B165","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/smll.202304378","article-title":"In Vivo mRNA CAR T Cell Engineering via Targeted Ionizable Lipid Nanoparticles with Extrahepatic Tropism","volume":"20","author":"Billingsley","year":"2024","journal-title":"Small"},{"key":"B166","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.ircmb.2022.04.007","article-title":"mRNA-based therapies: Preclinical and clinical applications","volume":"372","author":"Qureischi","year":"2022","journal-title":"Int Rev Cell Mol Biol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2023.08.005","article-title":"Chimeric antigen receptor therapy meets mRNA technology","volume":"42","author":"Wu","year":"2024","journal-title":"Trends Biotechnol"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.867013","article-title":"The past, present, and future of non-viral CAR T cells","volume":"13","author":"Moretti","year":"2022","journal-title":"Front Immunol"},{"key":"B169","doi-asserted-by":"publisher","first-page":"6080","DOI":"10.1038\/s41467-020-19486-2","article-title":"In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo","volume":"11","author":"Parayath","year":"2020","journal-title":"Nat Commun"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1016\/j.retram.2018.03.003","article-title":"Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy","volume":"66","author":"Gauthier","year":"2018","journal-title":"Curr Res Transl Med"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.01.011","article-title":"Inducible caspase-9 selectively modulates the toxicities of CD19-specific chimeric antigen receptor-modified T cells","volume":"25","author":"Diaconu","year":"2017","journal-title":"Mol Ther"},{"key":"B174","doi-asserted-by":"publisher","first-page":"020","DOI":"10.1038\/s41467-020-19486-2","article-title":"In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo","volume":"11","author":"Parayath","year":"2020","journal-title":"Nat Commun"},{"key":"B175","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J Clin Oncol"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"New Engl J Med"},{"key":"B179","doi-asserted-by":"publisher","first-page":"16011","DOI":"10.1038\/mto.2016.11","article-title":"Toxicity and management in CAR T-cell therapy","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol Ther  Oncolytics"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-022-01272-6","article-title":"CAR T-cell therapy in the older person: indications and risks","volume":"24","author":"Shouse","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.03.012","article-title":"Safety and efficacy of BCMA CAR-T cell therapy in older patients with multiple myeloma","volume":"29","author":"Reyes","year":"2023","journal-title":"Transpl Cell Ther"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02711","article-title":"CAR T cells beyond cancer: hope for immunomodulatory therapy of infectious diseases","volume":"10","author":"Seif","year":"2019","journal-title":"Front Immunol"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-580068","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2013.46","article-title":"Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors","volume":"10","author":"Kochenderfer","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"B186","doi-asserted-by":"publisher","first-page":"3008226","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Trans Med"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"New Engl J Med"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2016.10.020","article-title":"Phase 1 results of ZUMA-1: A multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma","volume":"25","author":"Locke","year":"2017","journal-title":"Mol Ther"},{"key":"B189","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/stem.2715","article-title":"Concise review: emerging principles from the clinical application of chimeric antigen receptor T cell therapies for B cell Malignancies","volume":"36","author":"Jain","year":"2018","journal-title":"Stem Cells"},{"key":"B190","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1126\/scitranslmed.3006960","article-title":"Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide","volume":"5","author":"Kanakry","year":"2013","journal-title":"Sci Trans Med"},{"key":"B191","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/s41467-022-28611-2","article-title":"TrkB agonist antibody ameliorates fertility deficits in aged and cyclophosphamide-induced premature ovarian failure model mice","volume":"13","author":"Qin","year":"2022","journal-title":"Nat Commun"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1089\/bio.2021.0159","article-title":"Protective effects of antioxidants on cyclophosphamide-induced ovarian toxicity","volume":"21","author":"Barberino","year":"2023","journal-title":"Biopreserv Biobank"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.02.060","article-title":"Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice","volume":"134","author":"Elinav","year":"2008","journal-title":"Gastroenterology"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2022.03.030","article-title":"Study design: human leukocyte antigen class I molecule A(\u2217)02-chimeric antigen receptor regulatory T cells in renal transplantation","volume":"7","author":"Schreeb","year":"2022","journal-title":"Kidney Int Rep"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1005457","article-title":"Practical aspects of chimeric antigen receptor T-cell administration: From commercial to point-of-care manufacturing","volume":"13","author":"Martinez-Cibrian","year":"2022","journal-title":"Front Immunol"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"B197","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3390\/biom10020263","article-title":"Recent advances in allogeneic CAR-T cells","volume":"10","author":"Kim","year":"2020","journal-title":"Biomolecules"},{"key":"B198","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201607485","article-title":"Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts","volume":"9","author":"Hartmann","year":"2017","journal-title":"EMBO Mol Med"},{"key":"B200","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3390\/cells7100155","article-title":"Allogeneic CAR-T cells: more than ease of access","volume":"7","author":"Graham","year":"2018","journal-title":"Cells"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0329-2","article-title":"The therapeutic landscape for cells engineered with chimeric antigen receptors","volume":"38","author":"MacKay","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.17","article-title":"Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity","volume":"21","author":"Lamers","year":"2013","journal-title":"Mol Ther"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1101\/gr.171322.113","article-title":"Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins","volume":"24","author":"Kim","year":"2014","journal-title":"Genome Res"},{"key":"B204","doi-asserted-by":"publisher","first-page":"04766","DOI":"10.7554\/eLife.04766.010","article-title":"Enhanced homology-directed human genome engineering by controlled timing of CRISPR\/Cas9 delivery","volume":"15","author":"Lin","year":"2014","journal-title":"Elife"},{"key":"B205","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nbt.3081","article-title":"Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo","volume":"33","author":"Zuris","year":"2015","journal-title":"Nat Biotechnol"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2016.142","article-title":"CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells[M","volume":"27","author":"Liu","year":"2017","journal-title":"Cell Res"},{"key":"B207","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s40164-023-00450-x","article-title":"CRISPR\/Cas9-mediated knockout of intracellular molecule SHP-1 enhances tumor-killing ability of CD133-targeted CAR T cells in vitro[M","volume":"12","author":"Liu","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3863","article-title":"CRISPR\/cas9-engineered universal CD19\/CD22 dual-targeted CAR-T cell therapy for relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"27","author":"Hu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021933","article-title":"Development of autoantibodies before the clinical onset of systemic lupus erythematosus","volume":"349","author":"Arbuckle","year":"2003","journal-title":"New Engl J Med"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1016\/j.cden.2013.06.003","article-title":"Systemic lupus erythematosus: epidemiology, pathophysiology, manifestations, and management","volume":"57","author":"Fortuna","year":"2013","journal-title":"Dental Clinics North America"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-023-00720-1","article-title":"Pathogenesis of autoimmune disease","volume":"19","author":"Pisetsky","year":"2023","journal-title":"Nat Rev Nephrol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1613878\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T04:10:51Z","timestamp":1754971851000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1613878\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":211,"alternative-id":["10.3389\/fimmu.2025.1613878"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1613878","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]},"article-number":"1613878"}}